Form 4 for RLAY Relay Therapeutics, Inc.
Accepted 2024-07-01 00:00:00 ET · period of report 2024-06-30 · accession 0000950170-24-079693 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-01 | 2024-06-30 | RLAY | Patel Sanjiv | Pres, CEO, Dir | A - Grant | $5.54 | +2,108 | 766.1K | +0.3% | +$11.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-30 | A | A | 2,108 | $5.54 | 766,130 | D | — | — | (F2) In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 28, 2024. (F3) Includes 762,360 shares underlying restricted stock units. |